Contrasting Barinthus Biotherapeutics (NASDAQ:BRNS) & Oncobiologics (NASDAQ:OTLK)

Oncobiologics (NASDAQ:OTLK) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk.

Valuation & Earnings

This table compares Oncobiologics and Barinthus Biotherapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	N/A	N/A	-$75.37 million	($0.57)	-3.67
Barinthus Biotherapeutics	$14.97 million	1.92	-$61.07 million	($1.88)	-0.37

Barinthus Biotherapeutics has higher revenue and earnings than Oncobiologics. Oncobiologics is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Oncobiologics and Barinthus Biotherapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1	4	1	0	2.00
Barinthus Biotherapeutics	1	0	2	0	2.33

Oncobiologics presently has a consensus price target of $6.50, suggesting a potential upside of 211.00%. Barinthus Biotherapeutics has a consensus price target of $4.00, suggesting a potential upside of 468.18%. Given Barinthus Biotherapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than Oncobiologics.

Volatility and Risk

Oncobiologics has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500. Comparatively, Barinthus Biotherapeutics has a beta of -0.67, suggesting that its share price is 167% less volatile than the S&P 500.

Institutional and Insider Ownership

11.2% of Oncobiologics shares are owned by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. 4.8% of Oncobiologics shares are owned by insiders. Comparatively, 10.7% of Barinthus Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Oncobiologics and Barinthus Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-332.30%
Barinthus Biotherapeutics	N/A	-70.13%	-56.09%

Summary

Barinthus Biotherapeutics beats Oncobiologics on 9 of the 12 factors compared between the two stocks.

About Oncobiologics

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.